1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Monoclonal Antibodies
1.2.3 Checkpoint Inhibitors
1.2.4 Oncoloytic Viral Therapies and Cancer Vaccines
1.3 Market by Application
1.3.1 Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Melanoma
1.3.6 Prostate Cancer
1.3.7 Head and neck Cancer
1.3.8 Ovarian Cancer
1.3.9 Pancreatic Cancer
1.3.10 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Oncolytic Virus Cancer Immunotherapy Market Perspective (2017-2028)
2.2 Oncolytic Virus Cancer Immunotherapy Growth Trends by Region
2.2.1 Oncolytic Virus Cancer Immunotherapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Oncolytic Virus Cancer Immunotherapy Historic Market Size by Region (2017-2022)
2.2.3 Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2028)
2.3 Oncolytic Virus Cancer Immunotherapy Market Dynamics
2.3.1 Oncolytic Virus Cancer Immunotherapy Industry Trends
2.3.2 Oncolytic Virus Cancer Immunotherapy Market Drivers
2.3.3 Oncolytic Virus Cancer Immunotherapy Market Challenges
2.3.4 Oncolytic Virus Cancer Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue
3.1.1 Global Top Oncolytic Virus Cancer Immunotherapy Players by Revenue (2017-2022)
3.1.2 Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Players (2017-2022)
3.2 Global Oncolytic Virus Cancer Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncolytic Virus Cancer Immunotherapy Revenue
3.4 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio
3.4.1 Global Oncolytic Virus Cancer Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncolytic Virus Cancer Immunotherapy Revenue in 2021
3.5 Oncolytic Virus Cancer Immunotherapy Key Players Head office and Area Served
3.6 Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
3.7 Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Type
4.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Type (2017-2022)
4.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2028)
5 Oncolytic Virus Cancer Immunotherapy Breakdown Data by Application
5.1 Global Oncolytic Virus Cancer Immunotherapy Historic Market Size by Application (2017-2022)
5.2 Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)
6.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type
6.2.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)
6.2.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)
6.2.3 North America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)
6.3 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application
6.3.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)
6.3.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)
6.3.3 North America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)
6.4 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country
6.4.1 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)
6.4.2 North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)
7.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type
7.2.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)
7.2.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)
7.2.3 Europe Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)
7.3 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application
7.3.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)
7.3.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)
7.3.3 Europe Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)
7.4 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country
7.4.1 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)
7.4.2 Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)
8.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type
8.2.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)
8.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application
8.3.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region
8.4.1 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)
9.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type
9.2.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)
9.2.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)
9.2.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)
9.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application
9.3.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)
9.3.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)
9.3.3 Latin America Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)
9.4 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country
9.4.1 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)
9.4.2 Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size (2017-2028)
10.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type
10.2.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Type (2017-2028)
10.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application
10.3.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country
10.4.1 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Oncolytic Virus Cancer Immunotherapy Introduction
11.1.4 AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.1.5 AstraZeneca Recent Developments
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Oncolytic Virus Cancer Immunotherapy Introduction
11.2.4 Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.2.5 Amgen Recent Developments
11.3 F Hoffman-La Roche
11.3.1 F Hoffman-La Roche Company Details
11.3.2 F Hoffman-La Roche Business Overview
11.3.3 F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Introduction
11.3.4 F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.3.5 F Hoffman-La Roche Recent Developments
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.4.5 Bristol-Myers Squibb Recent Developments
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Oncolytic Virus Cancer Immunotherapy Introduction
11.5.4 Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.5.5 Novartis AG Recent Developments
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Details
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Introduction
11.6.4 Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.6.5 Merck & Co., Inc. Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Oncolytic Virus Cancer Immunotherapy Introduction
11.7.4 Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.7.5 Pfizer Recent Developments
11.8 Biovex
11.8.1 Biovex Company Details
11.8.2 Biovex Business Overview
11.8.3 Biovex Oncolytic Virus Cancer Immunotherapy Introduction
11.8.4 Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.8.5 Biovex Recent Developments
11.9 Cell Genesys
11.9.1 Cell Genesys Company Details
11.9.2 Cell Genesys Business Overview
11.9.3 Cell Genesys Oncolytic Virus Cancer Immunotherapy Introduction
11.9.4 Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.9.5 Cell Genesys Recent Developments
11.10 Crusade Laboratories
11.10.1 Crusade Laboratories Company Details
11.10.2 Crusade Laboratories Business Overview
11.10.3 Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Introduction
11.10.4 Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.10.5 Crusade Laboratories Recent Developments
11.11 Genelux Corporation
11.11.1 Genelux Corporation Company Details
11.11.2 Genelux Corporation Business Overview
11.11.3 Genelux Corporation Oncolytic Virus Cancer Immunotherapy Introduction
11.11.4 Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.11.5 Genelux Corporation Recent Developments
11.12 Lokon Pharma
11.12.1 Lokon Pharma Company Details
11.12.2 Lokon Pharma Business Overview
11.12.3 Lokon Pharma Oncolytic Virus Cancer Immunotherapy Introduction
11.12.4 Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.12.5 Lokon Pharma Recent Developments
11.13 MultiVir
11.13.1 MultiVir Company Details
11.13.2 MultiVir Business Overview
11.13.3 MultiVir Oncolytic Virus Cancer Immunotherapy Introduction
11.13.4 MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
11.13.5 MultiVir Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Monoclonal Antibodies
Table 3. Key Players of Checkpoint Inhibitors
Table 4. Key Players of Oncoloytic Viral Therapies and Cancer Vaccines
Table 5. Global Oncolytic Virus Cancer Immunotherapy Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 6. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 7. Global Oncolytic Virus Cancer Immunotherapy Market Size by Region (2017-2022) & (US$ Million)
Table 8. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2017-2022)
Table 9. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 10. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region (2023-2028)
Table 11. Oncolytic Virus Cancer Immunotherapy Market Trends
Table 12. Oncolytic Virus Cancer Immunotherapy Market Drivers
Table 13. Oncolytic Virus Cancer Immunotherapy Market Challenges
Table 14. Oncolytic Virus Cancer Immunotherapy Market Restraints
Table 15. Global Oncolytic Virus Cancer Immunotherapy Revenue by Players (2017-2022) & (US$ Million)
Table 16. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Players (2017-2022)
Table 17. Global Top Oncolytic Virus Cancer Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2021)
Table 18. Ranking of Global Top Oncolytic Virus Cancer Immunotherapy Companies by Revenue (US$ Million) in 2021
Table 19. Global 5 Largest Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue (CR5 and HHI) & (2017-2022)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oncolytic Virus Cancer Immunotherapy Product Solution and Service
Table 22. Date of Enter into Oncolytic Virus Cancer Immunotherapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 25. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2017-2022)
Table 26. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 27. Global Oncolytic Virus Cancer Immunotherapy Revenue Market Share by Type (2023-2028)
Table 28. Global Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 29. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2017-2022)
Table 30. Global Oncolytic Virus Cancer Immunotherapy Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 31. Global Oncolytic Virus Cancer Immunotherapy Revenue Share by Application (2023-2028)
Table 32. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 33. North America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
Table 34. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 35. North America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
Table 36. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 37. North America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 38. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 39. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
Table 40. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 41. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
Table 42. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 43. Europe Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 44. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 45. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
Table 46. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 47. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
Table 48. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2017-2022) & (US$ Million)
Table 49. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size by Region (2023-2028) & (US$ Million)
Table 50. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
Table 52. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 53. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
Table 54. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 55. Latin America Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 56. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2017-2022) & (US$ Million)
Table 57. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Type (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Application (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size by Country (2023-2028) & (US$ Million)
Table 62. AstraZeneca Company Details
Table 63. AstraZeneca Business Overview
Table 64. AstraZeneca Oncolytic Virus Cancer Immunotherapy Product
Table 65. AstraZeneca Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 66. AstraZeneca Recent Developments
Table 67. Amgen Company Details
Table 68. Amgen Business Overview
Table 69. Amgen Oncolytic Virus Cancer Immunotherapy Product
Table 70. Amgen Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 71. Amgen Recent Developments
Table 72. F Hoffman-La Roche Company Details
Table 73. F Hoffman-La Roche Business Overview
Table 74. F Hoffman-La Roche Oncolytic Virus Cancer Immunotherapy Product
Table 75. F Hoffman-La Roche Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 76. F Hoffman-La Roche Recent Developments
Table 77. Bristol-Myers Squibb Company Details
Table 78. Bristol-Myers Squibb Business Overview
Table 79. Bristol-Myers Squibb Oncolytic Virus Cancer Immunotherapy Product
Table 80. Bristol-Myers Squibb Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 81. Bristol-Myers Squibb Recent Developments
Table 82. Novartis AG Company Details
Table 83. Novartis AG Business Overview
Table 84. Novartis AG Oncolytic Virus Cancer Immunotherapy Product
Table 85. Novartis AG Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 86. Novartis AG Recent Developments
Table 87. Merck & Co., Inc. Company Details
Table 88. Merck & Co., Inc. Business Overview
Table 89. Merck & Co., Inc. Oncolytic Virus Cancer Immunotherapy Product
Table 90. Merck & Co., Inc. Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 91. Merck & Co., Inc. Recent Developments
Table 92. Pfizer Company Details
Table 93. Pfizer Business Overview
Table 94. Pfizer Oncolytic Virus Cancer Immunotherapy Product
Table 95. Pfizer Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 96. Pfizer Recent Developments
Table 97. Biovex Company Details
Table 98. Biovex Business Overview
Table 99. Biovex Oncolytic Virus Cancer Immunotherapy Product
Table 100. Biovex Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 101. Biovex Recent Developments
Table 102. Cell Genesys Company Details
Table 103. Cell Genesys Business Overview
Table 104. Cell Genesys Oncolytic Virus Cancer Immunotherapy Product
Table 105. Cell Genesys Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 106. Cell Genesys Recent Developments
Table 107. Crusade Laboratories Company Details
Table 108. Crusade Laboratories Business Overview
Table 109. Crusade Laboratories Oncolytic Virus Cancer Immunotherapy Product
Table 110. Crusade Laboratories Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 111. Crusade Laboratories Recent Developments
Table 112. Genelux Corporation Company Details
Table 113. Genelux Corporation Business Overview
Table 114. Genelux Corporation Oncolytic Virus Cancer Immunotherapy Product
Table 115. Genelux Corporation Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 116. Genelux Corporation Recent Developments
Table 117. Lokon Pharma Company Details
Table 118. Lokon Pharma Business Overview
Table 119. Lokon Pharma Oncolytic Virus Cancer Immunotherapy Product
Table 120. Lokon Pharma Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 121. Lokon Pharma Recent Developments
Table 122. MultiVir Company Details
Table 123. MultiVir Business Overview
Table 124. MultiVir Oncolytic Virus Cancer Immunotherapy Product
Table 125. MultiVir Revenue in Oncolytic Virus Cancer Immunotherapy Business (2017-2022) & (US$ Million)
Table 126. MultiVir Recent Developments
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncolytic Virus Cancer Immunotherapy Market Share by Type: 2021 VS 2028
Figure 2. Monoclonal Antibodies Features
Figure 3. Checkpoint Inhibitors Features
Figure 4. Oncoloytic Viral Therapies and Cancer Vaccines Features
Figure 5. Global Oncolytic Virus Cancer Immunotherapy Market Share by Application: 2021 VS 2028
Figure 6. Lung Cancer Case Studies
Figure 7. Breast Cancer Case Studies
Figure 8. Colorectal Cancer Case Studies
Figure 9. Melanoma Case Studies
Figure 10. Prostate Cancer Case Studies
Figure 11. Head and neck Cancer Case Studies
Figure 12. Ovarian Cancer Case Studies
Figure 13. Pancreatic Cancer Case Studies
Figure 14. Others Case Studies
Figure 15. Oncolytic Virus Cancer Immunotherapy Report Years Considered
Figure 16. Global Oncolytic Virus Cancer Immunotherapy Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 17. Global Oncolytic Virus Cancer Immunotherapy Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Oncolytic Virus Cancer Immunotherapy Market Share by Region: 2021 VS 2028
Figure 19. Global Oncolytic Virus Cancer Immunotherapy Market Share by Players in 2021
Figure 20. Global Top Oncolytic Virus Cancer Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncolytic Virus Cancer Immunotherapy as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Oncolytic Virus Cancer Immunotherapy Revenue in 2021
Figure 22. North America Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
Figure 23. North America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)
Figure 24. North America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)
Figure 25. North America Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)
Figure 26. United States Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Canada Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Europe Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
Figure 29. Europe Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)
Figure 30. Europe Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)
Figure 31. Europe Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)
Figure 32. Germany Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. France Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. U.K. Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Italy Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Russia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Nordic Countries Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Asia-Pacific Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
Figure 39. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)
Figure 40. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)
Figure 41. Asia Pacific Oncolytic Virus Cancer Immunotherapy Market Size Share by Region (2017-2028)
Figure 42. China Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Japan Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. South Korea Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Southeast Asia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. India Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Australia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 48. Latin America Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
Figure 49. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)
Figure 50. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)
Figure 51. Latin America Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)
Figure 52. Mexico Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. Brazil Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Middle East & Africa Oncolytic Virus Cancer Immunotherapy Market Size YoY (2017-2028) & (US$ Million)
Figure 55. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Type (2017-2028)
Figure 56. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Market Share by Application (2017-2028)
Figure 57. Middle East and Africa Oncolytic Virus Cancer Immunotherapy Market Size Share by Country (2017-2028)
Figure 58. Turkey Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 59. Saudi Arabia Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 60. UAE Oncolytic Virus Cancer Immunotherapy Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 61. AstraZeneca Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 62. Amgen Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 63. F Hoffman-La Roche Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 65. Novartis AG Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 66. Merck & Co., Inc. Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 67. Pfizer Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 68. Biovex Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 69. Cell Genesys Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 70. Crusade Laboratories Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 71. Genelux Corporation Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 72. Lokon Pharma Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 73. MultiVir Revenue Growth Rate in Oncolytic Virus Cancer Immunotherapy Business (2017-2022)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
